Targeted delivery of etoposide to osteosarcoma cells using poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanoparticles
TURKISH JOURNAL OF BIOLOGY, vol.41, no.5, pp.719-733, 2017 (SCI-Expanded, Scopus, TRDizin)
- Publication Type: Article / Article
- Volume: 41 Issue: 5
- Publication Date: 2017
- Doi Number: 10.3906/biy-1612-17
- Journal Name: TURKISH JOURNAL OF BIOLOGY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
- Page Numbers: pp.719-733
- Keywords: PHBV nanoparticle, folate targeting, etoposide, targeted drug delivery, osteosarcoma, CANCER-THERAPY, PROTEIN ADSORPTION, DRUG-RELEASE, MICROPARTICLES, APOPTOSIS, ASSAY
- Open Archive Collection: AVESIS Open Access Collection
- Hacettepe University Affiliated: Yes
Abstract
Folic acid (FA)-functionalized poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanoparticles were prepared to enhance the delivery efficiency of the anticancer drug etoposide for the clinical treatment of osteosarcoma. PHBV nanoparticles were synthesized by emulsification/solvent evaporation technique and obtained in the size range of 200-250 nm and zeta potential range of -21 and -27 mV. Encapsulation efficiency and in vitro drug release were studied. The cytotoxic, apoptotic, and necrotic effects of PHBV nanoparticles were also investigated using Saos-2 osteosarcoma cells. The results obtained in this study demonstrate that etoposide-loaded and FA-functionalized PHBV nanoparticles can be successfully used for targeted treatment of osteosarcoma.